Earnings call transcript: Saluda Medical misses revenue view in Q1 2026 as stock slips
Saluda Medical reported $23.1 million in revenue for Q1 2026, representing a 26% year-over-year increase but falling short of analysts' expectations by $2.4 million. The company's stock dropped 1.89% to $0.26 in premarket trading, hovering near its 52-week low. Despite the revenue miss, Saluda's growth in U.S. sales and patient implants, driven by CAP24's full commercial release, indicates strong momentum.
The company's full-year FY2027 guidance remains optimistic, projecting revenue growth of 25% to 35%, a gross margin of 50% to 52%, and an adjusted EBITDA loss of $101 million to $95 million.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Earnings call transcript: Embassy REIT posts strong Q2 2026 beat on profit, revenue investing.com
- ServiceNow reports Q3 subscription revenue up 21% YoY to $3.99B, forecasts Q4 current remaining performance obligations below est.; NOW drops 15%+ after hours (Brody Ford/Bloomberg) bloomberg.com
- Alphabet reports Q3 YouTube ad revenue up 9% YoY to $11.2B, below estimates, and Google ad revenue hit $82.01B, up from $74.18B in Q3 2025 (Todd Spangler/Variety) variety.com
